{ "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What does Elucidata do for life sciences and biopharma companies?", "acceptedAnswer": { "@type": "Answer", "text": "Elucidata partners with life sciences and biopharma organizations to solve complex biomedical data challenges. Through Polly, its AI-powered data platform, Elucidata helps teams harmonize, curate, integrate, and analyze multimodal datasets, enabling more efficient research, drug discovery, and data-driven decision-making." } }, { "@type": "Question", "name": "How does Elucidata help pharmaceutical companies accelerate drug discovery?", "acceptedAnswer": { "@type": "Answer", "text": "Elucidata helps pharmaceutical companies build research-ready data foundations by integrating and harmonizing diverse biomedical datasets. Its solutions support use cases such as target identification, biomarker discovery, patient stratification, and AI-driven drug discovery, helping R&D teams derive insights from complex data." } }, { "@type": "Question", "name": "How can Elucidata help harmonize complex biomedical and multiomics data?", "acceptedAnswer": { "@type": "Answer", "text": "Elucidata helps standardize and harmonize heterogeneous biomedical datasets across different formats, sources, and modalities. Through its Polly platform and data curation capabilities, organizations can transform fragmented datasets into structured, interoperable, and analysis-ready data for downstream research and discovery." } }, { "@type": "Question", "name": "Can Elucidata integrate clinical, omics, imaging, and other biomedical datasets?", "acceptedAnswer": { "@type": "Answer", "text": "Yes. Elucidata helps life sciences organizations integrate diverse data modalities, including clinical, genomics, transcriptomics, single-cell, spatial transcriptomics, and imaging data. This enables researchers to work with connected datasets and generate more comprehensive biological insights." } }, { "@type": "Question", "name": "How does Elucidata support biomarker discovery and patient stratification?", "acceptedAnswer": { "@type": "Answer", "text": "Elucidata enables biomarker discovery and patient stratification by helping research teams harmonize and connect clinical and molecular datasets. These integrated datasets can support the identification of relevant biological signatures, characterization of patient populations, and discovery of potential biomarkers." } }, { "@type": "Question", "name": "How can life sciences companies prepare their data for AI and machine learning?", "acceptedAnswer": { "@type": "Answer", "text": "Life sciences companies need high-quality, standardized, and interoperable data to build reliable AI and machine learning workflows. Elucidata helps organizations curate, harmonize, structure, and integrate biomedical data to create analysis-ready foundations for advanced analytics, machine learning, and AI-driven research." } }, { "@type": "Question", "name": "Does Elucidata provide customized data solutions for specific R&D use cases?", "acceptedAnswer": { "@type": "Answer", "text": "Yes. Elucidata works with life sciences organizations to address specific research and development challenges through use case-driven data solutions. These can include data harmonization, multiomics integration, knowledge graph development, biomarker discovery, patient stratification, and AI-ready data infrastructure." } }, { "@type": "Question", "name": "How does Elucidata help computational biology and data science teams?", "acceptedAnswer": { "@type": "Answer", "text": "Elucidata supports computational biology and data science teams by reducing the complexity of working with fragmented, heterogeneous biomedical datasets. Its data curation, harmonization, and integration capabilities help teams access structured, research-ready data for computational analysis, biological discovery, and AI model development." } }, { "@type": "Question", "name": "What is Polly, and how does it support life sciences research?", "acceptedAnswer": { "@type": "Answer", "text": "Polly is Elucidata's AI-powered biomedical data platform that helps organizations integrate, harmonize, curate, and explore complex life sciences data. It supports research workflows by making multimodal biomedical datasets more accessible, standardized, and ready for downstream analysis and discovery." } }, { "@type": "Question", "name": "How can organizations work with Elucidata to solve their data challenges?", "acceptedAnswer": { "@type": "Answer", "text": "Organizations can collaborate with Elucidata to identify their biomedical data challenges, define specific research use cases, and develop solutions aligned with their R&D objectives. Elucidata combines domain expertise, data engineering, and its Polly platform to help life sciences teams build scalable data foundations and accelerate research workflows." } } ] }
.webp)





.webp)

.webp)


.webp)

.webp)


.webp)





.webp)

.webp)

.webp)

.webp)


.webp)





.webp)

.webp)


.webp)

.webp)


.webp)





.webp)

.webp)

.webp)

.webp)


Teams need to evaluate 10–20 competing targets simultaneously across modalities, with no reliable framework.
You bring your differentiated therapeutic thesis and proprietary data. Elucidata co-builds a program-specific target decision system that connects evidence & surfaces targets your team can act on.
We harmonize your proprietary omics, assay, and experimental data, connect it to curated evidence from 20+ public sources, and run quality checks before it enters the graph, turning 20,000 genes into an evidence-linked target landscape.
The knowledge graph is built around your program context and not just a broad disease label. It connects evidence across genetics, transcriptomics, proteomics, and disease mechanisms for every target, and helps filter generic associations into program-relevant targets.
Each target is ranked using a custom scoring framework aligned to your differentiated therapeutic thesis. Our in-silico perturbation model stress-tests hits across unscreened, disease-relevant contexts to show which signals are likely to hold up.
Your team gets a Target Dashboard with evidence grades for each target across genetics, multi-modal omics, disease biology, druggability, and confidence level. Every ranked candidate includes mechanistic rationale and source-linked evidence, helping your team decide which 2 targets are worth investing in.
Polly ingests your proprietary data and public biomedical evidence, connects it through a knowledge graph, scores candidates across 14 dimensions, and delivers a ranked, decision-ready target list your team can defend.
LLMs summarize papers. Generic AI Tools surface associations. We build knowledge graphs & models that show the mechanistic trail behind every target recommendation.

A Massachusetts-based therapeutics company sought to accelerate AML target-indication assessment using differentiation therapy, a novel approach that transforms malignant cells into healthy functional ones.

A Boston-based biotech focused on immune and metabolic diseases was hampered by siloed non-model datasets; our scalable ETL pipeline and Base-KG unified them into one AI-ready foundation from day one.

In collaboration with Elucidata, a US-based therapeutics company identified a novel Acute Myeloid Leukemia target in just 6 months. It has advanced to clinical trials, offering hope to 100k+ patients.

A pharmaceutical company based in Boston aimed to speed up their target discovery and validation process for inflammatory disease using single-cell RNA-seq data.